{"nctId":"NCT01112267","briefTitle":"An Efficacy and Safety Study of Extended Release (ER) Tramadol Hydrochloride (HCl)/Acetaminophen in Participants With Chronic Low-Back Pain","startDateStruct":{"date":"2009-05"},"conditions":["Low Back Pain"],"count":248,"armGroups":[{"label":"Tramadol Hydrochloride (HCl)/acetaminophen","type":"EXPERIMENTAL","interventionNames":["Drug: Tramadol HCl/acetaminophen Extended Release"]},{"label":"Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo"]}],"interventions":[{"name":"Tramadol HCl/acetaminophen Extended Release","otherNames":["Ultracet Extended Relaese"]},{"name":"Placebo","otherNames":[]},{"name":"Tramadol HCl/acetaminophen Extended Release","otherNames":["Ultracet Extended Relaese"]},{"name":"Placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Participants diagnosed with low back pain at least 3 months before the screening or washout period\n* Participants who have taken a stable dose of Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) (drugs used for reducing inflammation and pain ) or Cyclo-Oxygenase 2 (COX-2) selective inhibitors (an anti-inflammatory drug that fights pain) from 7 days before investigational product administration, and could maintain the same dose during the period of the study\n* Participants whose average pain intensity is more than or equal to 4.0 centimeters on Visual Analog Scale over the last 48 hours after the completion of screening\n* Postmenopausal or surgically sterile or abstinent women or practicing a highly effective method of birth control\n* Women with childbearing potential must have negative pregnancy test\n\nExclusion Criteria:\n\n* Participants who have taken tramadol or tramadol HCl or acetaminophen, or narcotic (strong habit-forming drug that stops pain and depresses the central nervous system) analgesic tablet within 30 days before investigational product administration\n* Participants who have taken acetaminophen tablet within 7 days before investigational product administration\n* Participants with tumor or infection in meninges or spinal cord\n* Participants who have fibromyalgia (neurosensory disorder characterized by muscle pain, joint stiffness, and fatigue), reflex sympathetic dystrophy (feeling of pain associated with evidence of minor nerve injury) or causalgia (persistent, severe burning sensation of the skin), acute spinal cord compression, acute nerve root compression, severe lower extremity weakness or numbness, regional pain syndrome, meningitis (inflammation of the meninges), diskitis (nonbacterial inflammation of an intervertebral disk or disk space), back pain because of secondary infection or tumor, or pain caused by a confirmed or suspected neoplasm\n* Participants who have taken analgesic (including local agents or anesthetics), sedative-hypnotic (e.g., diazepam), or muscle relaxant other than a stable dose of NSAIDs or COX-2 selective inhibitors within 5 times the half-life of the concerned agent before investigational product administration","healthyVolunteers":false,"sex":"ALL","minimumAge":"25 Years","maximumAge":"75 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Percentage of Participants With Reduction in Pain Intensity","description":"The percentage of participants with extent of reduction in pain intensity greater than or equal to 30 percent was reported. Pain intensity change rate was calculated by Visual Analog Scale (VAS) score at baseline minus VAS score at Day 29 divided by VAS score at Baseline. VAS is a 10 centimeter (cm) scale. Intensity of pain range: 0 cm=no pain to 10 cm=worst possible pain.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"57.65","spread":null},{"groupId":"OG001","value":"41.11","spread":null}]}]}]},{"type":"PRIMARY","title":"Change From Baseline in Pain Intensity at Day 29","description":"Change in pain intensity experienced by participants over the last 48 hours was measured on Day 29 against Baseline with VAS. VAS is a 10 cm scale. Intensity of pain range: 0 cm=no pain to 10 cm=worst possible pain.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"6.334","spread":"1.383"},{"groupId":"OG001","value":"6.000","spread":"1.331"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.299","spread":"1.764"},{"groupId":"OG001","value":"1.549","spread":"1.578"}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With Pain Relief","description":"Pain relief was measured in 6 stages to assess the participant's pain relief. Extent of pain relief was measured on a scale ranging from 4 to -1, where 4=complete disappearance, 3=fair relief, 2=moderate relief, 1=slight relief, 0=no change and -1=pain worsening. Relief more than 'slight relief (1)' was considered as pain relief success.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"70.73","spread":null},{"groupId":"OG001","value":"53.41","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"82.35","spread":null},{"groupId":"OG001","value":"65.17","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"81.18","spread":null},{"groupId":"OG001","value":"77.53","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Short Form (SF)-36 Score at Day 29","description":"The quality of life of participants was evaluated by SF-36 Korean version questionnaire. It is composed of 8 domains: physical and social functioning, physical and emotional role limitations, bodily pain, general health, vitality, mental health. Participants answered to the questionnaire of 36 questions; and physical, social, and psychological health status were assessed. It ranges 0 to 100, and higher score indicates better quality of life, But in \"Reported (Rptd.) Health Transition\" domain higher score indicates worse quality of life.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"46.71","spread":"20.71"},{"groupId":"OG001","value":"47.94","spread":"20.80"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"9.82","spread":"18.35"},{"groupId":"OG001","value":"6.67","spread":"15.99"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"44.93","spread":"24.18"},{"groupId":"OG001","value":"49.51","spread":"26.17"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"16.04","spread":"23.89"},{"groupId":"OG001","value":"8.69","spread":"22.62"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"34.66","spread":"14.46"},{"groupId":"OG001","value":"35.99","spread":"13.89"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"19.39","spread":"18.99"},{"groupId":"OG001","value":"17.69","spread":"14.84"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"43.56","spread":"17.92"},{"groupId":"OG001","value":"48.11","spread":"17.05"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7.36","spread":"14.41"},{"groupId":"OG001","value":"2.77","spread":"12.58"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"38.82","spread":"19.93"},{"groupId":"OG001","value":"42.71","spread":"17.83"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"11.14","spread":"20.55"},{"groupId":"OG001","value":"5.82","spread":"18.94"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"64.26","spread":"22.59"},{"groupId":"OG001","value":"64.58","spread":"26.98"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"11.75","spread":"25.70"},{"groupId":"OG001","value":"6.61","spread":"20.60"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"61.76","spread":"27.41"},{"groupId":"OG001","value":"61.57","spread":"29.34"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"8.13","spread":"28.93"},{"groupId":"OG001","value":"7.47","spread":"28.25"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"61.06","spread":"19.03"},{"groupId":"OG001","value":"60.56","spread":"19.34"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"20.48","spread":"23.20"},{"groupId":"OG001","value":"18.39","spread":"24.61"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"65.00","spread":"24.76"},{"groupId":"OG001","value":"63.61","spread":"20.92"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-18.07","spread":"25.99"},{"groupId":"OG001","value":"-6.90","spread":"30.19"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Oswestry Disability Index (ODI) Korean Version Score at Day 29","description":"The ODI Korean version was used to assess the participant's functionality. The ODI is a low back pain-specific, validated instrument that consists of questions related to limitations in performing specific activities of daily living and 1 question related to pain intensity. The ODI is a self-administered questionnaire consists of 10 sections. Each section consists of 6 statements ranked from 0 to 5 (0=good to 5=worse). Total score is the sum of score obtained in each section and ranges from 0 to 50. A higher score represents greater disability.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"39.626","spread":"12.239"},{"groupId":"OG001","value":"38.126","spread":"13.518"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"11.216","spread":"11.856"},{"groupId":"OG001","value":"7.178","spread":"13.879"}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With Investigator's Global Assessment on Investigational Product","description":"Global assessment on investigational product was done by investigator on how well the investigational product controlled chronic (lasting a long time) low back pain. Assessment was done by categories 'Very bad (-2)' 'Bad (-1)' 'Not changed (0) 'Good (1)' and 'Very good (2)'. Assessment better than \"Good\" was considered as pain improvement success. Percentage of participants with pain improvement success is reported here.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"81.25","spread":null},{"groupId":"OG001","value":"69.88","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With Participants' Global Assessment on Investigational Product","description":"Global assessment on investigational product was done by participants on how well the investigational product controlled chronic (lasting a long time) low back pain. Assessment was done by categories 'Very bad (-2)' 'Bad (-1)' 'Not changed (0) 'Good (1)' and 'Very good (2)'. Assessment better than \"Good\" was considered as pain improvement success. Percentage of participants with pain improvement success is reported here.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"76.25","spread":null},{"groupId":"OG001","value":"72.29","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":1,"n":125},"commonTop":["Nausea","Dizziness","Constipation","Vomiting","Dyspepsia"]}}}